BlackRock
EWTX icon

BlackRock’s Edgewise Therapeutics EWTX Stock Holding History

BlackRock’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$268M Buy
6,606,336
+133,345
+2% +$4.6M ﹤0.01% 1615
2026
Q1 		$204M Sell
6,472,991
-157,585
-2% -$4.54M ﹤0.01% 1660
2025
Q4 		$165M Buy
6,630,576
+279,089
+4% +$5.6M ﹤0.01% 1808
2025
Q3 		$103M Sell
6,351,487
-429,559
-6% -$6.09M ﹤0.01% 2084
2025
Q2 		$88.9M Buy
6,781,046
+296,038
+5% +$4.27M ﹤0.01% 2121
2025
Q1 		$143M Buy
6,485,008
+5,993
+0.1% +$157K ﹤0.01% 1785
2024
Q4 		$173M Buy
6,479,015
+85,448
+1% +$2.72M ﹤0.01% 1755
2024
Q3 		$171M Buy
6,393,567
+377,856
+6% +$7.52M ﹤0.01% 1754
2024
Q2 		$108M Buy
6,015,711
+848,705
+16% +$14.8M ﹤0.01% 1971
2024
Q1 		$94.2M Buy
5,167,006
+1,859,896
+56% +$29.6M ﹤0.01% 2086
2023
Q4 		$36.2M Buy
3,307,110
+321,266
+11% +$2.26M ﹤0.01% 2675
2023
Q3 		$17.1M Sell
2,985,844
-148,324
-5% -$1.01M ﹤0.01% 3030
2023
Q2 		$24.3M Buy
3,134,168
+263,161
+9% +$2.22M ﹤0.01% 2912
2023
Q1 		$19.1M Sell
2,871,007
-2,617
-0.1% -$24.3K ﹤0.01% 2999
2022
Q4 		$25.7M Buy
2,873,624
+758,154
+36% +$7.11M ﹤0.01% 2896
2022
Q3 		$20.8M Buy
2,115,470
+61,902
+3% +$625K ﹤0.01% 3009
2022
Q2 		$16.3M Sell
2,053,568
-1,592
-0.1% -$12K ﹤0.01% 3195
2022
Q1 		$19.9M Buy
2,055,160
+7,557
+0.4% +$97.3K ﹤0.01% 3175
2021
Q4 		$31.3M Buy
2,047,603
+1,467,371
+253% +$26.4M ﹤0.01% 2995
2021
Q3 		$9.63M Buy
580,232
+12,774
+2% +$231K ﹤0.01% 3692
2021
Q2 		$12.1M Buy
567,458
+511,973
+923% +$14M ﹤0.01% 3579
2021
Q1 		$1.8M Buy
+55,485
New +$1.8M ﹤0.01% 4316

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock's EWTX Position: Q2 2026 in Review

BlackRock increased its Edgewise Therapeutics (EWTX) stake by 2.1% in Q2 2026, buying an estimated $4.6M and bringing the position to 6,606,336 shares worth $268M. The position accounts for ﹤0.01% of the portfolio, ranked #1615.

BlackRock first reported a position in EWTX in Q1 2021 and has held it in 22 quarters since. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • BlackRock held 6,606,336 shares of Edgewise Therapeutics worth $268M as of Q2 2026.
  • BlackRock bought 133,345 Edgewise Therapeutics shares in Q2 2026, an estimated $4.6M.
  • Edgewise Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1615 holding.
  • BlackRock first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.